DE3689246D1 - Physiologisch aktives Polypeptid BUF-3. - Google Patents

Physiologisch aktives Polypeptid BUF-3.

Info

Publication number
DE3689246D1
DE3689246D1 DE86109029T DE3689246T DE3689246D1 DE 3689246 D1 DE3689246 D1 DE 3689246D1 DE 86109029 T DE86109029 T DE 86109029T DE 3689246 T DE3689246 T DE 3689246T DE 3689246 D1 DE3689246 D1 DE 3689246D1
Authority
DE
Germany
Prior art keywords
buf
physiologically active
active polypeptide
polypeptide
physiologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE86109029T
Other languages
English (en)
Other versions
DE3689246T2 (de
Inventor
Yuzuru Eto
Tomoko Tsuji
Satoshi Takano
Misako Takezawa
Yasunori Yokogawa
Hiroshiro Shibai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of DE3689246D1 publication Critical patent/DE3689246D1/de
Application granted granted Critical
Publication of DE3689246T2 publication Critical patent/DE3689246T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE3689246T 1985-07-03 1986-07-02 Physiologisch aktives Polypeptid BUF-3. Expired - Lifetime DE3689246T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP14631585 1985-07-03
JP17083985 1985-08-02
JP19727685 1985-09-06
JP28456385 1985-12-18

Publications (2)

Publication Number Publication Date
DE3689246D1 true DE3689246D1 (de) 1993-12-09
DE3689246T2 DE3689246T2 (de) 1994-05-26

Family

ID=27472707

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3689246T Expired - Lifetime DE3689246T2 (de) 1985-07-03 1986-07-02 Physiologisch aktives Polypeptid BUF-3.

Country Status (4)

Country Link
US (1) US5847078A (de)
EP (1) EP0210461B1 (de)
JP (1) JPH0637520B2 (de)
DE (1) DE3689246T2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215893A (en) * 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5089396A (en) * 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides
SE8701004D0 (sv) * 1987-03-11 1987-03-11 Astra Ab Method for therapy of leukemias and certain other malignancies
US5032507A (en) * 1987-11-13 1991-07-16 The Salk Institute For Biological Studies Potentiation of erythropoiesis
ATE118351T1 (de) * 1988-05-31 1995-03-15 Biotech Australia Pty Ltd Wirkung von hormonen.
US5071834A (en) * 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
AU8761391A (en) * 1990-09-13 1992-04-15 Children's Hospital Medical Center Of Northern California Method for increasing red blood cell production by treatment with activin or activin-related peptides
US5487895A (en) * 1993-08-13 1996-01-30 Vitaphore Corporation Method for forming controlled release polymeric substrate
WO1995005161A1 (en) * 1993-08-13 1995-02-23 Vitaphore Corporation Hydrogel-based microsphere drug delivery systems
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
CA2891010C (en) * 2004-07-23 2022-09-20 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP2329837B1 (de) 2005-11-23 2014-04-30 Acceleron Pharma Inc. Anti-Aktivin A- oder B-Antikörper und deren Verwendung zur Förderung von Knochenwachstum
US8895016B2 (en) * 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
EP2446896A1 (de) * 2006-12-18 2012-05-02 Acceleron Pharma, Inc. Activin-AcrtRII-Antagonisten zur Verwendung zur Erhöhung der Erythrozytenspiegel, zur Erhöhung der Reticulozytenspiegel oder zur Förderung der Erythropoiesis
RU2473362C2 (ru) * 2007-02-01 2013-01-27 Акселерон Фарма Инк. АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
TW201627320A (zh) * 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
ES2756725T3 (es) 2007-02-09 2020-04-27 Acceleron Pharma Inc Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIA
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
KR20220002710A (ko) * 2008-06-26 2022-01-06 악셀레론 파마 인코포레이티드 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
PL3494986T3 (pl) 2008-08-14 2020-11-16 Acceleron Pharma Inc. Pułapki GDF
US8138142B2 (en) 2009-01-13 2012-03-20 Acceleron Pharma Inc. Methods for increasing adiponectin in a patient in need thereof
CN104840944A (zh) * 2009-06-08 2015-08-19 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
WO2010151426A1 (en) 2009-06-12 2010-12-29 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
WO2011056896A1 (en) * 2009-11-03 2011-05-12 Acceleron Pharma Inc. Methods for treating fatty liver disease
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CA2817008A1 (en) 2010-11-08 2012-05-18 Acceleron Pharma Inc. Actriia binding agents and uses thereof
EP2914277B1 (de) 2012-11-02 2017-09-13 Celgene Corporation Activin-actrii-antagonisten und verwendungen zur behandlung von knochen- und anderen erkrankungen
EP3154566B1 (de) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist zur behandlung oder prävention eines hautulzers in einem patienten mit anämie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
SI3227675T1 (sl) 2014-12-03 2023-07-31 Celgene Corporation Antagonisti aktivin-actrii in uporaba za zdravljenje mielodisplastičnega sindroma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6028934A (ja) * 1983-07-25 1985-02-14 Green Cross Corp:The 細胞分化誘導物質
JPS60105621A (ja) * 1983-11-14 1985-06-11 Agency Of Ind Science & Technol 細胞の分化誘導作用を有する生理活性物質およびその製法
DE3650689T2 (de) * 1985-04-18 1999-04-08 Biotech Australia Pty Ltd Rekombinantes inhibin
JP2652534B2 (ja) * 1985-04-18 1997-09-10 バイオテクノロジー・オーストラリア・ピーテイーワイ・リミテツド 組換えインヒビン
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US4798885A (en) * 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
NZ217727A (en) * 1985-10-03 1990-05-28 Genentech Inc Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it
US4973577A (en) * 1986-04-04 1990-11-27 The Salk Institute For Biological Studies FSH-releasing peptides

Also Published As

Publication number Publication date
EP0210461A2 (de) 1987-02-04
JPS62240700A (ja) 1987-10-21
EP0210461A3 (en) 1989-03-08
JPH0637520B2 (ja) 1994-05-18
DE3689246T2 (de) 1994-05-26
US5847078A (en) 1998-12-08
EP0210461B1 (de) 1993-11-03

Similar Documents

Publication Publication Date Title
DE3689246D1 (de) Physiologisch aktives Polypeptid BUF-3.
DK151985A (da) Humant fysiologisk aktivt polypeptid
DE3786767D1 (de) Neues polypeptid.
NO863111D0 (no) Romaskin.
DE3686172D1 (de) Peptid-derivate.
DK496486A (da) Polypeptid
IT8619338A0 (it) Peptide sintetico ad attivita'interleukina 1 umana.
DK175487D0 (da) Farmaceutisk aktive 2-thiomethyl-substitueret-1,4-dihydro-pyridiner
DE3683186D1 (de) Rekombinantes humaninterleukin-1.
DE3685167D1 (de) Calcitoningen-verwandte peptidderivate.
NO892294D0 (no) Polypeptidforbindelser.
DK551287A (da) Polypeptid
DK383985A (da) Polypeptid
DK354389D0 (da) Polypeptid
NO870533D0 (no) Terapeutisk aktive 3-alkoksy-2-aminopropylaminer.
DK394084A (da) Fysiologisk aktive praeparater
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
DE3675679D1 (de) Menschliche bauchspeichelelastase.
NO853400L (no) Polypeptidvaksiner.
DE3586765D1 (de) Immunogenische hav-peptide.
ES555490A0 (es) Procedimiento de clonacion de factor humano viii-r.
DE3853743D1 (de) Rekombinanter menschlicher ADF.
DE3685636D1 (de) Lysozymbetreffende peptide.
DE3869939D1 (de) Biologisch wirksame peptide.
NO851435L (no) Stol.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition